Business Context and Reporting Period
This Form 8-K was filed by Oncogenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) on August 23, 2008. The filing reports a change in the registrant's certifying accountant effective August 23, 2008, following the completion of an Arrangement Agreement with OncoGenex Technologies Inc. dated May 27, 2008. As part of this transaction, the Company acquired all share capital and debentures of OncoGenex Technologies Inc., was renamed, and underwent a change in its board of directors and management.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. The document focuses exclusively on the administrative change of the independent registered public accounting firm.
Material Changes
- Accountant Change: The Audit Committee approved the engagement of Ernst & Young LLP (Canada) ("E&Y Canada") as the independent registered public accounting firm for the fiscal year ended December 31, 2008.
- Resignation: Ernst & Young LLP (US) ("E&Y US") resigned on August 26, 2008. The change was effected solely due to the completion of the Arrangement Agreement.
- Corporate Restructuring: The Company acquired OncoGenex Technologies Inc. in exchange for 3,449,393 shares, with certain shares placed in escrow pending milestone achievement.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. Regarding risks and contingencies, the Company stated that during the two most recent fiscal years and subsequent interim periods:
- There were no disagreements with E&Y US on accounting principles, practices, financial statement disclosure, or auditing scope.
- There were no "reportable events" as defined in Regulation S-K.
- The audit reports from E&Y US for the years ended December 31, 2007, and 2006 contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
- The Company did not consult with E&Y Canada regarding matters set forth in Item 304(a)(2)(i) or (ii) of Regulation S-K prior to this engagement.
Investor Verification Checklist
- Verify the terms of the Arrangement Agreement filed on August 21, 2008, regarding the acquisition of OncoGenex Technologies Inc.
- Confirm the status of the 3,449,393 shares issued in the transaction and the specific milestones required to release escrowed shares.
- Review the letter from E&Y US (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the change in accountant.
- Monitor future filings for the first financial statements audited by E&Y Canada for the fiscal year ending December 31, 2008.